Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EPS (Weighted Average and Diluted): 2020-2025

Historic EPS (Weighted Average and Diluted) for BridgeBio Pharma (BBIO) over the last 5 years, with Sep 2025 value amounting to -$0.95.

  • BridgeBio Pharma's EPS (Weighted Average and Diluted) fell 10.47% to -$0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.20, marking a year-over-year decrease of 74.27%. This contributed to the annual value of -$2.88 for FY2024, which is 27.09% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's EPS (Weighted Average and Diluted) is -$0.95, which was down 0.00% from -$0.95 recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's EPS (Weighted Average and Diluted) peaked at -$0.07 during Q2 2022, and registered a low of -$1.42 during Q4 2024.
  • For the 3-year period, BridgeBio Pharma's EPS (Weighted Average and Diluted) averaged around -$0.87, with its median value being -$0.95 (2025).
  • As far as peak fluctuations go, BridgeBio Pharma's EPS (Weighted Average and Diluted) soared by 93.97% in 2022, and later crashed by 1,300.00% in 2023.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's EPS (Weighted Average and Diluted) stood at -$1.02 in 2021, then rose by 9.80% to -$0.92 in 2022, then decreased by 4.35% to -$0.96 in 2023, then tumbled by 47.92% to -$1.42 in 2024, then dropped by 10.47% to -$0.95 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.95 for Q3 2025, versus -$0.95 for Q2 2025 and -$0.88 for Q1 2025.